IL-11 prevents IFN-γ-induced hepatocyte death through selective downregulation of IFN-γ/STAT1 signaling and ROS scavenging

Akimitsu Miyawaki, Yoshiko Iizuka, Hitomi Sugino, Yoshifumi Watanabe

Department of Pharmaceutical Sciences, Musashino University, Tokyo, Japan

*ywatanab@musashino-u.ac.jp

Abstract

Aims

Interferon-γ (IFN-γ) exhibits hepatotoxicity through signal transducer and activator of transcription 1 (STAT1) activation. On the contrary, interleukin-11 (IL-11) shows tissue-protective effects on various organs including the liver through STAT3 activation. Here, we found that IL-11 pretreatment protects hepatocytes from IFN-γ-induced death and investigated the molecular mechanisms, particularly focusing on signal crosstalk.

Methods and results

Primary culture mouse hepatocytes were treated with IL-11 prior to IFN-γ, and cell death was evaluated by lactate dehydrogenase release into media. As a result, IL-11 pretreatment effectively suppressed IFN-γ-induced hepatocyte death. Since IFN-γ-induced hepatocyte death requires STAT1 signaling, the activity of STAT1 was analyzed. IFN-γ robustly activated STAT1 with its peak at 1 hr after stimulation, which was significantly attenuated by IL-11 pretreatment. Consistently, IL-11 pretreatment impeded mRNA increase of STAT1-downstream molecules promoting cell death, i.e., IRF-1, caspase 1, bak, and bax. IL-11-mediated suppression of STAT1 signaling was presumably due to upregulation of the suppressor of cytokine signaling (SOCS) genes, which are well-known negative feedback regulators of the JAK/STAT pathway. Interestingly, however, IFN-γ pretreatment failed to affect the following IL-11-induced STAT3 activation, although IFN-γ also upregulated SOCSs. Finally, we demonstrated that IL-11 pretreatment mitigated oxidative stress through increasing expression of ROS scavengers.

Conclusion

IL-11 protects hepatocytes from IFN-γ-induced death via STAT1 signal suppression and ROS scavenging. Further investigation into the mechanisms underlying selective negative feedback regulation of IFN-γ/STAT1 signaling compared to IL-11/STAT3 signaling may shed new light on the molecular biology of hepatocytes.
**Introduction**

The liver possesses a strong ability to regenerate itself after injury, compared to other organs. For example, 70% hepatectomy results in almost complete recovery in liver mass by 21 days post-operation in mice [1]. In contrast, however, the regenerative capacity of the liver is gradually exhausted in situations of cumulative damage, such as chronic virus infection and alcoholic/nonalcoholic steatohepatitis [2]. These pathologies lead to fibrosis and, eventually, cirrhosis/carcinogenesis of the liver, which is hardly reversible and requires liver transplantation [3]. Therefore, it is of great importance to protect liver parenchymal cells, namely hepatocytes, from chronic damage in order to prevent liver disease progression.

It is widely accepted that dysregulated inflammatory cytokine expression plays a pivotal role in the progression of chronic liver diseases [4]. Among the inflammatory cytokines, we have previously reported that interferon-gamma (IFN-γ) by itself exhibits hepatotoxic effects through upregulation of interferon regulatory factor-1 (IRF-1), a downstream proapoptotic molecule of IFN-γ/signal transducer and activator of transcription 1 (STAT1) signaling [5]. IFN-γ was originally identified as an antiviral agent and has since been found to possess pleiotropic immunomodulatory functions [6–8]. Recently, it has been reported that IFN-γ is upregulated in steatohepatitis without infection, contributing to augmentation of inflammatory responses and progression of the disease [9]. Therefore, protecting hepatocytes from IFN-γ-induced death has potential therapeutic implications in liver diseases.

Interleukin-11 (IL-11) is an IL-6 family cytokine but can exhibit anti-inflammatory properties unlike IL-6 [10,11]. Activating STAT3 upon binding to its receptor, IL-11 protects a variety of organs including the liver by suppressing inflammation. For example, IL-11 administration significantly attenuates acetaminophen-induced hepatic injury through downregulation of tumor necrosis factor-α (TNF-α) [12]. It has also been reported that IL-11 mitigates liver ischemia/reperfusion injury with decreased expression of proinflammatory cytokines [13,14]. In addition to its anti-inflammatory functions, IL-11/STAT3 signaling renders resistance against oxidative stress by upregulating reactive oxygen species (ROS) scavengers, such as manganese superoxide dismutase (MnSOD) and metallothioneins (MTs) [15,16]. In fact, IL-11 contributes to the reduction of oxidative stress in the acetaminophen-induced liver injury model [17].

Although the hepatoprotective roles of IL-11 have been recognized, its potential in restraining cytokine-induced hepatotoxicity remains unexplored. Hence, in this study, we investigated the effects of IL-11 on IFN-γ-induced hepatocyte death and found that IL-11-pretreated hepatocytes were resistant to the following IFN-γ stimulation. Since both cytokines activate the common Janus kinase (JAK)/STAT cascade, the mechanism of IL-11-mediated protection from IFN-γ was studied with an intensive focus on signal crosstalk in addition to ROS scavenging. The data we present here reveal new aspects of signal regulation in hepatocytes.

**Materials and methods**

**Study approval**

Animal care was conducted under the supervision of the Institutional Animal Experiments Committee of Musashino University. All experimental procedures conformed to the *Guide for the Care and Use of Laboratory Animals: Eighth Edition*, updated by the US National Research Council Committee in 2011, and were approved by the Institutional Animal Experiments Committee of Musashino University.
**Hepatocyte primary culture**

Eight-ten-week old female ICR mice were euthanized by cervical dislocation under isoflurane anesthesia. Primary hepatocytes were obtained as described previously [18] with minor modifications. In brief, hepatic cells were isolated from the liver by perfusing 0.0125% collagenase type X (Wako, Osaka, JP), followed by passing through a 70-μm opening mesh. Hepatocytes were purified two times by centrifugation at 50 g for 2 min. Nonparenchymal cells in the supernatant were discarded. Dead hepatocytes were removed by density gradient centrifugation in 45% Percoll (GE Healthcare, Buckingham, GB) at 50 g for 10 min. The obtained hepatocytes were then suspended in William’s Medium E (Sigma, St. Louis, US) supplemented with 10% fetal bovine serum (FBS) (Japan Bio Serum, Fukuyama, JP) and seeded on collagen-coated dishes at \(10^5\) cells/mL. The media were changed to William’s Medium E containing 2% FBS 3 hr after seeding.

**Evaluation of hepatocyte death**

Hepatocyte death was evaluated by lactate dehydrogenase (LDH) release into media, which was measured with CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, US) in accordance with the manufacturer’s protocol. Absorbance at 490 nm was measured by iMark Microplate Absorbance Reader (Bio-Rad, Hercules, US). For a positive control, hepatocytes were lysed with the attached Lysis Solution, and the activity of released LDH was considered to represent 100% cell death.

**Quantitative RT-PCR**

Total RNA was obtained using QIAzol lysis reagent (QIAGEN, Hilden, DE), and complementary DNA (cDNA) was synthesized from the RNA using ReverTra Ace -α- (TOYOBO, Osaka, JP). The resulting cDNA was applied for following quantitative RT-PCR (qRT-PCR) experiments with THUNDERBIRD SYBR qPCR Mix (TOYOBO, Osaka, JP) and the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, US). All the procedures were conducted in accordance with the manufacturer’s protocol. The primer pairs used are listed below.

- **β-actin**
  - forward: 5’-CATCCGTAAGACCTCTATGCAAC-3’,
  - reverse: 5’-ATGGAGCCACCGATCCACA-3’.
- **bak**
  - forward: 5’-CAACCCCCGAGATGGGACAACCT-3’,
  - reverse: 5’-CTGAGCGGCGGTTATATCAT-3’.
- **bax**
  - forward: 5’-TGAAGACAGGGCCTTTTGT-3’,
  - reverse: 5’-AATTCGCCGGAGACACTCG-3’.
- **bim**
  - forward: 5’-CCCGGAGATACGGATTGCAC-3’,
  - reverse: 5’-GCCTCGCCCGGTTATATCAT-3’.
- **caspase 1**
  - forward: 5’-ACAGGAAGACCGGGATTGCAC-3’,
  - reverse: 5’-GCTCTCGGCTAGGATGATGC-3’.
- **IRF-1**
  - forward: 5’-TCACACAGGCGCCATACAAAG-3’,
  - reverse: 5’-CACACGGAAGTTTGCCT-3’.
- **MnSOD** [19]
  - forward: 5’-CTTCAATAAGGAGCCAGGTCC-3’,
reverse: 5’-TGAAGGTAGTAAGCGTGCTC-3’.
MT1 [19]
forward: 5’-CGTAGCTCCAGCTACCAGATCTC-3’,
reverse: 5’-TGGTGCGAGCGCTTGTGCT-3’.
MT2 [19]
forward: 5’-GCTTTTTGGGTCGGACCAATACTCTC-3’,
reverse: 5’-GGAGCAGCAGCTTTTCTTGCAGGAAG-3’.
SOCS1
forward: 5’-CTGCGGCTTCTATTGGGGAC-3’,
reverse: 5’-AAAAGGCACGGTGAAGTCTCG-3’.
SOCS3
forward: 5’-ATGGTCACCCACAGCAAGTTT-3’,
reverse: 5’-TCCAGTAGAATCCGCTCTC-3’.

Immunoblot analysis
Hepatocytes were scraped in buffer containing 150 mmol/L NaCl, 50 mmol/L Tris-HCl (pH 6.8), 1% Triton X-100, 0.1% SDS, 1 mM dithiothreitol, phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, JP), and protease inhibitor cocktail (Wako, Osaka, JP). After denaturing at 96˚C for 6 min, the resulting protein samples were separated by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Millipore, Burlington, US). Immunoblotting was performed with the following primary antibodies at 1/500 or 1/1000 (for β-actin only). β-actin: PM053-7 (MBL, Nagoya, JP). STAT1: 14994 (CST, Danvers, US). pSTAT1: 7649 (CST, Danvers, US). STAT3: 4904 (CST, Danvers, US). pSTAT3: 9145 (CST, Danvers, US). SOCS1: sc-518028 (Santa Cruz Biotechnology, Dallas, US). SOCS3: ab16030 (Abcam, Cambridge, UK). HRP-conjugated goat anti-rabbit IgG (CST, Danvers, US) was applied at 1/1000 as secondary antibody. Chemiluminescence of Clarity Western ECL Substrate (Bio-Rad, Hercules, US) or ECL Prime Western Blotting Detection Reagent (GE Healthcare, Buckingham, GB) was detected by ImageQuant LAS 4000 (GE Healthcare, Buckingham, GB).

Cytokine stimulation
Hepatocytes were stimulated by IFN-γ (PeproTech, Rocky Hill, US) or IL-11 (PeproTech, Rocky Hill, US) at 100 U/mL or 100 ng/mL, respectively. For JAK inhibition, 2.5 μM Ruxolitinib (SYNkinase, Parkville, AU) was applied.

Dihydroethidium assay
Hepatocytes were pretreated with 100 ng/mL IL-11. Sixteen hr after IL-11 pretreatment, the cells were stimulated by 100 U/mL IFN-γ. Dihydroethidium (DHE) (Cayman, Ann Arbor, US) at 20 μM was added to the media 8 hr after the IFN-γ stimulation and incubated for 30 min, followed by substituting the media to PBS and microscopic observation with BZ-X710 (Keyence, Osaka, JP). Pictures were taken from the center of wells of a 96-well culture plate with a 4x objective lens. The capture area of each picture was approximately 0.13 cm². Since hepatocytes were seeded at 10000 cells/well and bottom area of each well was 0.32 cm², approximately 4000 cells were estimated to be within a picture. Fluorescence intensity of four independent pictures (approximately 16000 cells in total) was calculated for each experimental group. In the ImageJ analysis, the entire area of each picture was surrounded with a square and fluorescence within the square was quantified.
Statistics

For comparison between two groups, Welch’s t test was applied. Multiple groups were compared with one-way ANOVA, followed by post-hoc tests. The statistical significance level was set at $P < 0.05$. Data were presented as mean ± S.D. and specified in S1 Table.

Results

IFN-γ-induced hepatocyte death was mediated by JAK/STAT1 signaling

We have previously shown that IFN-γ induces hepatocyte death via induction of interferon regulatory factor-1 (IRF-1), which is an apoptosis-promoting transcription factor upregulated by STAT1 [5]. In order to confirm that the JAK/STAT1 pathway is responsible for the IFN-γ-induced hepatocyte death, hepatocytes were treated with IFN-γ in combination with Ruxolitinib (Rux), a JAK1/JAK2 inhibitor. As a result, Rux completely blocked STAT1 activation (Fig 1A) and an increase in LDH release from hepatocytes (Fig 1B) induced by IFN-γ, verifying that STAT1 activation is indispensable for hepatocyte death.

IL-11 pretreatment prevented IFN-γ-induced hepatocyte death

Since IL-11 exerts many of its functions via induction of transcriptional activation by STAT3 [20], we pretreated hepatocytes with IL-11 prior to IFN-γ stimulation to evaluate its effects. Hepatocytes, when stimulated with IFN-γ, formed apoptotic bodies, which were apparently suppressed by IL-11 pretreatment (Fig 2A). Consistently, LDH release from hepatocytes was significantly reduced and Caspase 3 cleavage became slightly milder in the IL-11-pretreated groups (Fig 2B; S1 Fig). It may be of note that IL-11 not only inhibited IFN-γ-induced death but also hampered the baseline death of hepatocytes, which is in line with previous reports describing the broad spectrum of cytoprotective functions of STAT3 [21,22].

IL-11 pretreatment suppressed STAT1 signal activation by IFN-γ

Hepatocyte death induced by IFN-γ is dependent on STAT1 activation as described above. Therefore, we hypothesized that IL-11 pretreatment mitigated hepatocyte death by influencing STAT1 signaling. IFN-γ stimulation alone increased phosphorylated STAT1 (pSTAT1), which peaked 1 hr after stimulation and returned to an undetectable level by 24 hr (Fig 3A). At later time points, i.e., 8 hr and 24 hr, the total amount of STAT1 increased, instead of pSTAT1, due to transcriptional activation of STAT1 by itself [23,24]. It should be noted that IFN-γ stimulation also activated STAT3, the phosphorylation pattern of which traced the same time-dependent vicissitude as that of STAT1.

Next, IL-11 was used for pretreatment before IFN-γ stimulation. As a result, the intense STAT1 phosphorylation 1 hr post-IFN-γ stimulation was hampered by IL-11 pretreatment (Fig 3B). We also examined mRNA expression of STAT1-downstream molecules promoting cell death and revealed that IRF-1, caspase-1, bak, bax, and bim were upregulated by IFN-γ, which was significantly restrained by IL-11 pretreatment, except for bim (Fig 3C).

Either IFN-γ or IL-11 stimulation upregulated SOCs

In order to clarify the mechanism of prompt deactivation of STAT1s after IFN-γ stimulation, we examined expression of the suppressor of cytokine signaling (SOCS) family genes. mRNA of both SOCS1 and SOCS3, potent negative feedback regulators of IFN-γ/JAK/STAT signaling [25–27], was upregulated after IFN-γ stimulation (Fig 4A). Since IL-11 as well as IFN-γ, signals through JAK/STAT cascade, it is reasonable that IL-11 also upregulated mRNA of SOCs (Fig 4B). We also examined protein expression of SOCs after IFN-γ stimulation with/without IL-
A

CTRL  IFN-γ  IFN-γ +Rux

pSTAT1

STAT1

β-actin

B

LDH release

**  **

CTRL  IFN-γ  IFN-γ +Rux
11 pretreatment. Consistent with mRNA expression, both SOCS1 and SOCS3 proteins were increased 16 hr after IL-11 treatment (Fig 4C). At 4 hr after IFN-\(\gamma\) stimulation, SOCS1 was induced in the IL-11 and/or IFN-\(\gamma\)-treated groups, while SOCS3 protein induction was hardly observed (Fig 4D). In the IL-11-treated groups, upregulation of SOCS1 was sustained until 24 hr after IFN-\(\gamma\) stimulation. On the other hand, SOCS1 protein induction was terminated at this time point when only IFN-\(\gamma\) was applied, although mRNA expression remained at a high level (Fig 4A and 4E). Taken together, SOCSs, although mRNA and protein expression patterns may not completely correspond, are upregulated upon activation of STATs, mediating negative feedback regulation of IFN-\(\gamma\) signaling, but not IL-11.

**IFN-\(\gamma\) pretreatment failed to affect STAT3 activation by IL-11**

In order to fully clarify the signal cross-regulation between IFN-\(\gamma\) and IL-11, we further tested the effect of IFN-\(\gamma\) pretreatment on IL-11-induced STAT3 activation. When hepatocytes were stimulated with IL-11 alone, STAT3, but not STAT1, was strongly activated (Fig 5A). It is of note that the activation of STAT3 was observed immediately after stimulation and prolonged at least until 24 hr without apparent decline, which is a remarkable difference from IFN-\(\gamma\) signaling. Even when IFN-\(\gamma\) was used for pretreatment, IL-11-induced STAT3 activation was unaffected (Fig 5B). Considering that both IFN-\(\gamma\) and IL-11 upregulated SOCSs but only IFN-\(\gamma\) signaling was transient and was suppressed by pretreatment of the other, it is conceivable that negative feedback regulation by SOCSs exhibits a preference for IFN-\(\gamma\) signaling to IL-11 signaling in hepatocytes.

**IL-11 conferred oxidative stress resistance to hepatocytes**

We have previously reported that IFN-\(\gamma\) stimulation induces oxidative stress, which is also required for hepatocyte death [28], while IL-11/STAT3 signaling is known to promote ROS resistance [17]. As another aspect of hepatocyte protection by IL-11, we finally investigated whether hepatocytes acquired ROS resistance after IL-11 treatment. mRNA expression of IL-11/STAT3-downstream ROS scavengers, MnSOD, MT1, and MT2 [15,16], were found to be increased by IL-11 (Fig 6A). Intracellular ROS levels were analyzed by DHE, the oxidized form of which emits red fluorescence. IFN-\(\gamma\) stimulation alone significantly increased ROS in hepatocytes, which was completely blocked by IL-11 pretreatment (Fig 6B). Taken together, IL-11 pretreatment protected hepatocytes from IFN-\(\gamma\)-induced death through two distinct mechanisms: downregulating STAT1 signaling and conferring ROS resistance.

**Discussion**

Although IL-11 has been known to protect the liver in the contexts of acetaminophen-induced and ischemia/reperfusion injury [12–14,17], its role in cytokine-induced hepatocyte damage remained unrevealed. In this study, we addressed the effects of IL-11 on hepatocyte death induced by IFN-\(\gamma\). As a result, IL-11 pretreatment significantly attenuated IFN-\(\gamma\)-induced hepatocyte death by suppressing STAT1 signaling, while IFN-\(\gamma\)-pretreatment showed a negligible effect on IL-11-induced STAT3 activation. Additionally, IL-11 enhanced the ROS scavenging capacity of hepatocytes, which could further support its protective function.
Fig 2. IFN-γ-induced hepatocyte death was mitigated by IL-11 pretreatment. Hepatocytes were pretreated with IL-11, followed by IFN-γ stimulation 16 hr after IL-11 pretreatment. (A) Microscopic observation was performed 48 hr after IFN-γ stimulation. Bar: 100 μm. Arrows: apoptotic bodies. (B) LDH release was analyzed 48 hr after IFN-γ stimulation. Data were shown as mean ± S.D. n = 4. One-way ANOVA, ""P < 0.01.

https://doi.org/10.1371/journal.pone.0211123.g002
Figure 3
IFN-γ exhibits its hepatotoxic effects from relatively later time points, i.e., 24 hr after stimulation, indicating that secondary or even latter stage effectors, including IRF-1, are essential for promoting cell death [5,18,29]. As such, it is possible that the increase in unphosphorylated STAT1 observed from 8 hr after IFN-γ stimulation (Fig 3A) also played a role in damaging hepatocytes. In human fibroblasts or mammary epithelial cells, for example, unphosphorylated STAT1 accumulating in response to IFN-β or IFN-γ is important in maintaining expression of a subset of IFN-responsive genes [30]. Actually, we found that IRF-1, which was upregulated from as early as 1 hr after IFN-γ stimulation, remained at a high level at least until 48 hr (S2 Fig), though pSTAT1 had returned to an inactive state much earlier. Thus, IFN-γ-induced hepatocyte death may still harbor undisclosed mechanistic aspects including the relevance of unphosphorylated STAT1. However, IL-11 pretreatment is expected to interfere with these cytotoxic machineries comprehensively, since it hampered STAT1 phosphorylation, a major primary phase of IFN-γ-mediated cytotoxicity.

IL-11 is known to exhibit its protective function through not only STAT3 but also other signaling cascades, such as Akt and ERK. Actually, we investigated the activation status of known IL-11-downstream molecules [31,32] and found that Akt and ERK, but not p38 were phosphorylated upon IL-11 treatment (S3 Fig). Although it is possible that these molecules as well as STAT3 are coordinately mediating hepatocyte protection, we focused particularly on STAT signaling, since we believe that one of the most interesting findings in this study is the selective negative feedback regulation of STAT signaling. There are several possible interpretations for this selectivity. IFN-γ receptors and IL-11 receptors are associated with different subtypes of JAK from each other: JAK1 and JAK2 for ILN-γ and JAK1 alone for IL-11 [33]. Therefore, a hypothesis that SOCSs preferentially target JAK2 relative to JAK1 seems to be an attractive explanation for the selective IFN-γ signal inhibition. However, this idea is partially falsified by previous reports demonstrating that SOCS1 inhibits both JAK1 and JAK2 [34,35]. Furthermore, STAT3 phosphorylation by IL-6, utilizing only JAK1 under the receptor like IL-11, is suppressed by IFN-γ pretreatment in human endothelial cells [36]. Considering that IL-11 signaling was unaltered by IFN-γ pretreatment in our experiments, the JAK difference by itself cannot fully explain the selective negative feedback regulation of cytokine signaling, although species or cell type variation may be another key factor that determines which signaling is to be suppressed.

Since SOCSs bind to receptor-JAK complex rather than a JAK monomer in many situations [37–39], another possible model of the selective negative feedback regulation of IFN-γ signaling is that SOCSs have different affinities to receptor-JAK complex depending on the receptor type. Croker et al., using SOCS-deficient mouse hepatocytes, have studied specificity of SOCS1 and SOCS3 in inhibiting IFN-γ and IL-6 signaling and shown that SOCS1 is specific to IFN-γ, while SOCS3 is to IL-6 [40]. In our experiments, IL-11 induced sustained STAT3 activation despite upregulation of SOCS3, and IFN-γ signaling was downregulated by IL-11 pretreatment. Magrangeas et al. have featured signal crosstalk between IL-3 and IL-11 in Ba/F3 cells engineered to express IL-11 receptor [41]. They reported that IL-3 pretreatment inhibited STAT3 activation by subsequent IL-11 stimulation through STAT5/SOCS3 cascade, whereas IL-11 pretreatment did not affect IL-3-induced STAT5 activation. Taken together, IL-11 receptor-

Fig 3. IFN-γ-induced STAT1 activation was suppressed by IL-11 pretreatment. (A) Hepatocytes were stimulated by IFN-γ. Protein samples were collected at the indicated time points after stimulation and subjected to immunoblotting with anti-β-actin, STAT1, pSTAT1, STAT3, and pSTAT3 antibodies. (B, C) Hepatocytes were pretreated with IL-11, followed by IFN-γ stimulation 16 hr after IL-11 pretreatment. (B) Protein samples collected 1 hr after IFN-γ stimulation were subjected to immunoblotting with anti-β-actin, STAT1, and pSTAT1 antibodies. The pSTAT1 band density was quantified with ImageJ and normalized to that of β-actin. Data were shown as mean ± S.D. n = 4. Welch’s t-test, **P < 0.01. (C) RNA samples were collected 24 hr after IFN-γ stimulation for qRT-PCR. The expression levels of the indicated genes were normalized to that of β-actin and shown as mean ± S.D. n = 5. One-way ANOVA, *P < 0.05, **P < 0.01.

https://doi.org/10.1371/journal.pone.0211123.g003
Fig 4. SOCSs expression was increased by either IFN-γ or IL-11. (A) qRT-PCR was performed for hepatocyte RNA samples collected at the indicated time points after IFN-γ stimulation. The expression levels of the indicated genes were normalized to that of β-actin and shown as mean ± S.D. n = 4. One-way ANOVA, * P < 0.05, ** P < 0.01. (B) RNA samples collected from hepatocytes 16 hr after IL-11 stimulation were subjected to qRT-PCR. The expression levels of the indicated genes were normalized to that of β-actin and shown as mean ± S.D. n = 4. Welch’s t-test, ** P < 0.01. (C) Hepatocytes were treated with IL-11 and protein samples collected 16 hr after IL-11 stimulation were subjected to immunoblotting with anti-β-actin, SOCS1, and SOCS3 antibodies. (D) Protein samples were collected 4 hr after IFN-γ stimulation with/without IL-11 pretreatment and subjected to immunoblotting with the indicated antibodies. (E) Protein samples were collected 24 hr after IFN-γ stimulation with/without IL-11 pretreatment and subjected to immunoblotting with the indicated antibodies.

https://doi.org/10.1371/journal.pone.0211123.g004

Fig 5. IFN-γ pretreatment showed no mitigating effect on IL-11-induced STAT3 activation. (A) Hepatocytes were stimulated by IL-11. Protein samples were collected at the indicated time points after stimulation for immunoblotting with anti-β-actin, STAT1, pSTAT1, STAT3, and pSTAT3 antibodies. A protein sample collected 1 hr after IFN-γ stimulation was applied as a positive control of pSTAT1. (B) Hepatocytes were pretreated with IL-11 for 16 hr, followed by IFN-γ stimulation. Protein samples collected 1 hr after IFN-γ stimulation were subjected to immunoblotting with anti-β-actin, STAT3, and pSTAT3 antibodies. The pSTAT3 band density was quantified with ImageJ and normalized to that of β-actin. Data were shown as mean ± S.D. n = 4. Welch’s t-test, n.s.: not significant.

https://doi.org/10.1371/journal.pone.0211123.g005
JAK complex is not totally but relatively insensitive to SOCSs compared to IL-6 or IFN-γ receptor-JAK complex.

From the viewpoint of biological significance, it may be reasonable that IL-11 signaling overwhelms cytotoxic signal pathways. In the liver, IL-11 is known to be expressed from

Fig 6. Oxidative stress was reduced by IL-11 pretreatment. (A) Hepatocytes were stimulated by IL-11. RNA samples collected 16 hr after stimulation were subjected to qRT-PCR. The expression level of the indicated genes was normalized to that of β-actin and shown as mean ± S.D. n = 4. Welch’s t-test, *P < 0.05, **P < 0.01. (B) Hepatocytes were pretreated with IL-11 for 16 hr, followed by IFN-γ stimulation. DHE assay was performed 8 hr after IFN-γ stimulation. Bar: 100 μm. DHE fluorescence was quantified with ImageJ and shown as relative intensity. Fluorescence of approximately 16000 cells in total from four independent pictures was quantified for each group. One-way ANOVA, *P < 0.05, **P < 0.01.

https://doi.org/10.1371/journal.pone.0211123.g006
hepatocytes in response to oxidative stress [17,42], which could define the dominance of IL-11 over cytotoxic stimuli as a brake of hepatic damage to maintain tissue homeostasis. Future investigation into the selective negative feedback regulation of cytokine signals will lead to further understanding of molecular systems, which balance hepatocyte survival and death.

To conclude, we revealed for the first time the protective and dominant effect of IL-11 on hepatocytes challenged by IFN-γ, shedding new light on hepatocyte molecular biology.

**Supporting information**

S1 Fig. Caspase 3 activation after IFN-γ stimulation was attenuated by IL-11 pretreatment. Hepatocytes were pretreated with IL-11, followed by IFN-γ stimulation 16 hr after IL-11 pretreatment. Protein samples collected 24 hr after IFN-γ stimulation were subjected to immunoblotting with anti-Caspase 3 (9662, CST) antibody.

(DOCX)

S2 Fig. IRF-1 expression remained at a high level until 48 hr after IFN-γ stimulation. qRT-PCR was performed for hepatocyte RNA samples collected at the indicated time points after IFN-γ stimulation. The expression levels of the indicated genes were normalized to that of β-actin and shown as mean ± S.D. n = 4. One-way ANOVA, *P < 0.05, **P < 0.01.

(DOCX)

S3 Fig. Akt and ERK were activated after IL-11 treatment. Hepatocytes were treated with IL-11 and protein samples collected 1 hr after IL-11 stimulation were subjected to immunoblotting with indicated anti-pAkt (9271, CST), anti-Akt (9272, CST), anti-p-p38 (9211, CST), anti-p38 (8690, CST), anti-pERK (4370, CST), anti-ERK (9102, CST) and anti-β-actin antibodies.

(DOCX)

S4 Fig. Uncropped immunoblot images of main figures.

(DOCX)

S1 Table. Mean values and standard deviations.

(DOCX)

**Author Contributions**

**Conceptualization:** Akimitsu Miyawaki, Yoshifumi Watanabe.

**Data curation:** Akimitsu Miyawaki, Yoshiko Iizuka, Hitomi Sugino.

**Formal analysis:** Akimitsu Miyawaki, Yoshiko Iizuka, Hitomi Sugino.

**Investigation:** Akimitsu Miyawaki, Yoshiko Iizuka, Hitomi Sugino.

**Methodology:** Akimitsu Miyawaki, Yoshiko Iizuka, Yoshifumi Watanabe.

**Supervision:** Akimitsu Miyawaki, Yoshifumi Watanabe.

**Validation:** Akimitsu Miyawaki, Yoshiko Iizuka, Yoshifumi Watanabe.

**Visualization:** Akimitsu Miyawaki, Yoshiko Iizuka, Hitomi Sugino.

**Writing – original draft:** Akimitsu Miyawaki, Yoshiko Iizuka, Yoshifumi Watanabe.

**Writing – review & editing:** Akimitsu Miyawaki, Yoshiko Iizuka, Hitomi Sugino, Yoshifumi Watanabe.
References

1. Nikfarjam M, Malcontenti-Wilson C, Fanartzis M, Daruwalla J, Christophi C. A model of partial hepatectomy in mice. J Invest Surg. 2004; 17: 291–294. https://doi.org/10.1080/08941930490502871 PMID: 15385262

2. Tanaka M, Miyajima A. Liver regeneration and fibrosis after inflammation. Inflamm Regen. 2016; 36: 19. https://doi.org/10.1186/s41232-016-0025-2 PMID: 29259692

3. Dooley S, ten Dijke P. TGF-beta in progression of liver disease. Cell Tissue Res. 2012; 347: 245–256. https://doi.org/10.1007/s00441-011-1246-y PMID: 22006249

4. Szabo G, Petrasek J. Inflamasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015; 12: 387–400. https://doi.org/10.1038/nrgastro.2015.94 PMID: 26055245

5. Kano A, Haruyama T, Akaike T, Watanabe Y. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun. 1999; 257: 672–677. https://doi.org/10.1006/bbrc.1999.0276 PMID: 10208842

6. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997; 15: 749–795. https://doi.org/10.1146/annurev.immunol.15.1.749 PMID: 9143706

7. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004; 75: 163–189. https://doi.org/10.1189/jlb.0603252 PMID: 14525967

8. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science. 1965; 149: 310–311.

9. Luo XY, Takahara T, Kawai K, Fujino M, Sugiyama T, Tsuneyama K, et al. IFN-gamma deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet. Am J Physiol Gastrointest Liver Physiol. 2013; 305: G891–899. https://doi.org/10.1152/ajpgi.00193.2013 PMID: 24136786

10. Trepicchio WL, Wang L, Bozza M, Dorner AJ. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol. 1997; 159: 5661–5670. PMID: 9548510

11. Ellis M, Hedstrom U, Frampton C, Alizadeh H, Kristen sen J, Shammas FV, et al. Modulation of the systemic inflammatory response by recombinant human interleukin-11: a prospective randomized placebo controlled clinical study in patients with hematological malignancy. Clin Immunol. 2006; 120: 129–137. https://doi.org/10.1016/j.clim.2006.03.003 PMID: 16644288

12. Trepicchio WL, Bozza M, Bouchard P, Dorner AJ. Protective effect of rhIL-11 in a murine model of acetaminophen-induced hepatotoxicity. Toxicol Pathol. 2001; 29: 242–249. https://doi.org/10.1080/019263137052521 PMID: 11421492

13. Yu J, Feng Z, Tan L, Pu L, Kong L. Interleukin-11 protects mouse liver from warm ischemia/reperfusion (I/R) injury. Clin Res Hepatol Gastroenterol. 2016; 40: 562–570. https://doi.org/10.1016/j.clinre.2015.11.009 PMID: 27016892

14. Zhu M, Lu B, Cao Q, Wu Z, Xu Z, Li W, et al. IL-11 attenuates liver ischemia/reperfusion injury (IRI) through STAT3 signaling pathway in mice. PLoS One. 2015; 10: e0126296. https://doi.org/10.1371/journal.pone.0126296 PMID: 25946003

15. Waxman AB, Einarsson O, Seres T, Knickelbein RG, Warshaw JB, Johnston R, et al. Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest. 1998; 101: 1970–1982. https://doi.org/10.1172/JCI1337 PMID: 9576762

16. Obana M, Miyamoto K, Murasawa S, Iwakura T, Hayama A, Yamashita T, et al. Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am J Physiol Heart Circ Physiol. 2012; 303: H569–577. https://doi.org/10.1152/ajpheart.00060.2012 PMID: 22707562

17. Nishina T, Komazawa-Sakon S, Yanaka S, Piao X, Zheng DM, Piao JH, et al. Interleukin-11 links oxidative stress and compensatory proliferation. Sci Signal. 2012; 5: ra5. https://doi.org/10.1126/scisignal.2002056 PMID: 22253262

18. Morita M, Watanabe Y, Akaike T. Protective effect of hepatocyte growth factor on interferon-gamma-induced cytotoxicity in mouse hepatocytes. Hepatology. 1995; 21: 1585–1593. PMID: 7768503

19. Miyawaki A, Obana M, Mitsuhara Y, Orimoto A, Nakayasu Y, Yamashita T, et al. Adult murine cardiomyocytes exhibit regenerative activity with cell cycle reentry through STAT3 in the healing process of myocarditis. Sci Rep. 2017; 7: 1407. https://doi.org/10.1038/s41598-017-01426-8 PMID: 28469272

20. Xu DH, Zhu Z, Wakefield MR, Xiao H, Bai Q, Fang Y. The role of IL-11 in immunity and cancer. Cancer Lett. 2016; 373: 156–163. https://doi.org/10.1016/j.canlet.2016.01.004 PMID: 26826523

21. Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 2016; 138: 2570–2578. https://doi.org/10.1002/ijc.29923 PMID: 26559373
22. Szczepanek K, Chen Q, Larner AC, Lesnfsky EJ. Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. Mitochondrion. 2012; 12: 180–189. https://doi.org/10.1016/j.mito.2011.08.011 PMID: 21930250

23. Lehtonen A, Matikainen S, Julkunen I. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol. 1997; 159: 794–803. PMID: 9218597

24. Satoh J, Tabunoki H. A comprehensive profile of ChIP-seq-based STAT1 target genes suggests the complexity of STAT1-mediated gene regulatory mechanisms. Gene Regul Syst Bio. 2013; 7: 41–56. https://doi.org/10.4137/GRSB.S11433 PMID: 23645984

25. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. 1998; 273: 35056–35062. PMID: 9857039

26. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 1999; 98: 597–608. PMID: 10490099

27. Starr R, Fuchsberger M, Lau LS, Uldrich AP, Goradia A, Willson TA, et al. SOCS-1 binding to tyrosine 441 of IFN-gamma receptor subunit 1 contributes to the attenuation of IFN-gamma signaling in vivo. J Immunol. 2009; 183: 4537–4544. https://doi.org/10.4049/jimmunol.0901010 PMID: 19734231

28. Watanabe Y, Suzuki O, Haruyama T, Akaike T. Interferon-gamma induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis. J Cell Biochem. 2003; 89: 244–253. https://doi.org/10.1002/jcb.10501 PMID: 12704788

29. Kano A, Watanabe Y, Takeda N, Aizawa S, Akaike T. Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. J Biochem. 1997; 121: 677–683. PMID: 9163517

30. Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A. 2009; 106: 9373–9378. https://doi.org/10.1073/pnas.0903487106 PMID: 23549086

31. Onnis B, Feron V, Rapisarda A, Perez VS, Melillo G. Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. J Clin Invest. 2013; 123: 1615–1629. https://doi.org/10.1172/JCI59623 PMID: 23549086

32. Yang L, Wang R, Gao Y, Xu X, Fu K, Wang S, et al. The protective role of interleukin-11 against neutron radiation injury in mouse intestines via MEK/ERK and PI3K/Akt dependent pathways. Dig Dis Sci. 2014; 59: 1406–1414. https://doi.org/10.1007/s10620-013-3015-0 PMID: 24452839

33. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007; 178: 2623–2629. https://doi.org/10.4049/jimmunol.0901010 PMID: 17312100

34. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997; 387: 921–924. https://doi.org/10.1038/33213 PMID: 9202126

35. Iwamoto T, Senga T, Naito Y, Matsuda S, Miyake Y, Yoshimura A, et al. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation. Oncogene. 2000; 19: 4795–4801. https://doi.org/10.1038/sj.occ.17120309 PMID: 11302030

36. Bluyssen HA, Rastmanesh MM, Tilburgs C, Jie K, Wesseling S, Goumans MJ, et al. IFN-gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol. 2010; 299: C354–362. https://doi.org/10.1152/ajpcell.00513.2009 PMID: 20484656

37. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, et al. Suppressor of cytokine signal-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A. 2000; 97: 6493–6498. https://doi.org/10.1073/pnas.100135197 PMID: 10829066

38. Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F, SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem. 2000; 275: 12848–12856. PMID: 10775853

39. Kershaw NJ, Murphy JM, Liu NP, Varghese LN, Laktyushin A, Whitlock EL, et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol. 2013; 20: 469–476. https://doi.org/10.1038/nsmb.2519 PMID: 23454976

40. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 2003; 4: 540–545. https://doi.org/10.1038/nij31 PMID: 12754505

41. Magrangeas F, Boistseau O, Denis S, Jacques Y, Minvielle S. Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3). Biochem J. 2001; 353: 223–230. PMID: 11139384
Nishina T, Deguchi Y, Miura R, Yamazaki S, Shinkai Y, Kojima Y, et al. Critical contribution of nuclear factor erythroid 2-related factor 2 (NRF2) to electrophile-induced interleukin-11 production. J Biol Chem. 2017; 292: 205–216. https://doi.org/10.1074/jbc.M116.744755 PMID: 27872193